Pharmaceuticals

Telomir Pharmaceuticals

Telomir Pharmaceuticals released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0299 (forecast USD -0.07)

Telomir Pharmaceuticals released FY2025 Q4 earnings on March 17 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0615 (forecast USD -0.07)

Telomir Pharmaceuticals released FY2025 annual earnings on March 17 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3289 (forecast USD -0.38)

Telomir-1 Drug Shows Good Safety in Studies, Telomir Pharmaceuticals Plans IND Application in 2026

Telomir Pharmaceuticals released FY2025 9 Months Earnings on November 10 (EST), with actual revenue of USD 0 and EPS of USD -0.2762

Telomir Pharmaceuticals released FY2025 Q3 earnings on November 10 EST, with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD 0 (forecast USD -0.07)

Telomir Pharmaceuticals released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1699 (forecast USD -0.08)

Telomir Pharmaceuticals released FY2025 Semi-Annual Earnings on August 14 (EST), with actual revenue of USD 0 and EPS of USD -0.2395

Telomir-1 shows significant effect in reversing prostate cancer gene silencing

Telomir-1 Shows Promising Preclinical Data

Positive Preclinical Results for Telomir-1 in Treating Wilson's Disease

Positive Preclinical Results for Telomir-1 Drug

Telomir Pharmaceuticals Seeks Partnerships and Mergers at the International Biotech Conference

Telomir-1 Candidate Drug Shows Promising Preclinical Results in Treating AMD

Telomir Pharmaceuticals CFO Position Change

Telomir Pharmaceuticals Raises $3 Million in Equity Financing

Telomir Pharmaceuticals released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0732 (forecast USD -0.1)

Telomir Pharmaceuticals Announces Positive Results for Telomir-1 in Prostate Cancer Models

Telomir Pharmaceuticals released FY2024 annual earnings on February 4, 2025 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.5596 USD (forecast -0.54 USD)

Telomir Pharmaceuticals released FY2024 Q4 earnings on February 4, 2025 (EST), with actual revenue of 0 USD and EPS of -0.0977 USD (forecast EPS was -0.05 USD)

Akanda

Agape ATP

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

Tradr 2X Long QBTS Daily ETF

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Liminatus Pharma

LAFAYETTE ACQUISITION CORP ORD USD0.0001(S/R)24/10/2030

TELO

ARKG

SBIO

LABU

Telomir reported peer-reviewed preclinical data indicating that Telomir-Zn improves survival and reduces hepatic copper in a Wilson’s disease model. Key findings include reduced copper-driven ROS amplification, lower liver injury biomarkers, and improved locomotor performance in zebrafish. The company plans to continue its Wilson’s disease program and advance its Telomir-1 TNBC program toward Phase 1/2 clinical initiation.

TradingView

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

iShares US Pharma

VG Health

Health Care Select Sector SPDR

iShares Biotechnology ETF

VanEck Biotech ETF

Telomir Reports Peer-Reviewed Preclinical Telomir-Zn Data Showing Dose-Dependent Survival & Reduced Hepatic Copper

Earnings Watch

Telomir Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0

Telomir Pharmaceuticals, Inc. reported a net loss of $(990,947) with no revenue for Q1 2026, an improvement from a $(2,179,828) loss in Q1 2025. Diluted EPS was $(0.03), better than $(0.07) a year earlier. The FDA cleared an IND for Telomir-1 to begin trials for advanced triple-negative breast cancer. A merger with TELI consolidated global rights to Telomir-1. Bayshore Trust committed up to $5.0M for funding, with $1.0M tied to IND acceptance. Cash is sufficient to fund operations into Q1 2027.

Telomir Pharmaceuticals, Inc. 1Q 2026: Revenue $0 EPS $(0.03) — 10-Q Summary

Telomir Pharmaceuticals has received FDA clearance for its Investigational New Drug application for Telomir-Zn, allowing it to begin a Phase 1/2 clinical trial for advanced or metastatic triple-negative breast cancer (TNBC). The trial, set to start in the first half of 2026, will evaluate safety, tolerability, and efficacy in approximately 76 patients. The study will also incorporate biomarker analyses to assess treatment response and epigenetic changes. Telomir's stock fell 3.45% to $1.40 in premarket trading following the announcement.

benzinga_article

iShares Global Healthcare

Shutterstock

EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study

TEVA

Teva Pharmaceuticals plans to acquire Emalex Biosciences for $700 million, enhancing its late-stage pipeline. The deal, expected to close by Q3 2026, aligns with Teva's growth strategy. Teva reported Q1 earnings of 53 cents per share, surpassing expectations, with sales of $3.98 billion. The company maintains its 2026 outlook, targeting adjusted earnings of $2.57-$2.77 per share and sales of $16.4-$16.8 billion. A share buyback program is under consideration, contingent on market conditions. Teva's stock rose 11.4% to $35.14 following the news.

Teva Pharmaceutical Industries

Invesco Nasdaq Biotechnology ETF

Meta Platforms

Alphabet

Alphabet - C

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan

Telomir Pharmaceuticals has completed the acquisition of TELI Pharmaceuticals, securing global rights to its lead program, Telomir-1 (Telomir-Zn). The transaction, approved by shareholders, consolidates rights under one corporate structure and includes $1 million in initial funding, with potential for an additional $4 million based on clinical milestones. This acquisition allows Telomir to control development and commercialization across major markets, following its recent IND submission for Telomir-Zn aimed at treating advanced triple-negative breast cancer. The deal positions Telomir for clinical advancement and partnership opportunities.

Fidelity

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

BAYRY

LLYX

This week's biotech news highlights significant regulatory approvals, acquisitions, and clinical trial outcomes. ARS Pharma's Neffy nasal spray received FDA approval for broader use, while Novo Nordisk's Awiqli, a once-weekly insulin, gained FDA approval. Lupin and Teva also secured FDA approvals for generic and biosimilar products. Bayer expanded Kerendia's use in the EU, and GSK's Exdensur was approved in China. Eli Lilly announced its acquisition of Centessa Pharmaceuticals for approximately $6.3 billion in cash and contingent value rights.

rttnews

Bayer

Biogen

Direxion Daily LLY Bull 2X Shares

ARS Pharmaceuticals

Eli Lilly

Apellis Pharma

Centessa Pharmaceuticals

Novo Nordisk AS

Defiance Daily Target 2X Long NVO ETF

Defiance Daily Target 2X Long LLY ETF

Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS

Telomir Pharmaceuticals(TELO.US)